Cytokinetics, Incorporated
CYTK
Κατάταξη σε μετοχές
#2262
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Τιμή μετοχής
$64.11
Κεφαλαιοποίηση
$8.91B
Αλλαγή (1 ημέρα)
2.32%
Αλλαγή (1 έτος)
8.01%
Χώρα
US
Εμπόριο Cytokinetics, Incorporated (CYTK)
Κατηγορία
Healthcare
Κέρδη για την Cytokinetics, Incorporated (CYTK)
Κέρδη τον Jun 2026 TTM: $-894.00M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Cytokinetics, Incorporated, τα τρέχοντα κέρδη της εταιρείας είναι $-894.00M. Το 2023, η εταιρεία παρουσίασε κέρδη $-526.24M, μείωση σε σύγκριση με των κερδών του 2022 που ήταν $-388.96M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Cytokinetics, Incorporated από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-894.00M | 51.65% |
| 2024 | $-589.53M | 12.03% |
| 2023 | $-526.24M | 35.30% |
| 2022 | $-388.96M | 80.65% |
| 2021 | $-215.31M | 69.15% |
| 2020 | $-127.29M | 4.60% |
| 2019 | $-121.69M | 14.49% |
| 2018 | $-106.29M | -16.83% |
| 2017 | $-127.79M | -876.70% |
| 2016 | $16.45M | -143.87% |
| 2015 | $-37.50M | 156.05% |
| 2014 | $-14.65M | -56.56% |
| 2013 | $-33.72M | -13.58% |
| 2012 | $-39.02M | -18.48% |
| 2011 | $-47.86M | -3.24% |
| 2010 | $-49.46M | -300.30% |
| 2009 | $24.69M | -143.80% |
| 2008 | $-56.37M | 15.30% |
| 2007 | $-48.89M | -14.39% |
| 2006 | $-57.12M | 35.18% |
| 2005 | $-42.25M | 13.59% |
| 2004 | $-37.20M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | -690.03% |
US
|
|
| $-3.09B | 245.30% |
US
|
|
| $-4.02B | 349.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -318.19% |
NL
|
